Bio-Techne Corporation은 자회사들과 함께 전 세계 연구, 진단 및 바이오프로세싱 시장을 위한 생명과학 시약, 기기 및 서비스를 개발, 제조 및 판매합니다. 당사는 ...
$0.32 주당
예상 EPS $0.44 · 매출 $292.06M · 5 명의 애널리스트
예상 EPS $0.48 · 매출 $308.37M · 4 명의 애널리스트
예상 EPS $0.56 · 매출 $328.16M · 1 명의 애널리스트
$0.32 주당
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $1.2B | -0.4% | +3.1% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $181.9M | +147.8% | +7.0% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +65.8% | +1.5% | -1.6% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | +20.7% | +147.3% | -4.6% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | +15.0% | +148.7% | +3.7% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $263.2M | +2.6% | +12.1% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | +21.7% | +3.0% | +8.7% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 13.7% | -40.7% | -1.5% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 4.55x | +31.5% | +1.3% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $2.7B | +4.7% | +1.4% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | 1.16 vs 1.92 | -39.7% | 0.36 vs 0.44 | -18.2% |
| 매출 서프라이즈 | $1.2B vs $1.2B | +0.7% | $321.2M vs $292.1M | +10.0% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Bohnen Shane | officer: SVP - General Counsel | Restricted Stock Units | A | 18,432 | — |
| Aug 17, 2026 | Bohnen Shane | officer: SVP - General Counsel | Restricted Stock Units | A | 11,344 | — |
| Aug 17, 2026 | Kelderman Kim | director, officer: Chief Executive Officer | Restricted Stock Units | A | 93,582 | — |
| Aug 17, 2026 | Kelderman Kim | director, officer: Chief Executive Officer | Restricted Stock Units | A | 57,590 | — |
| Aug 17, 2026 | Hippel James | officer: CFO | Restricted Stock Units | A | 36,459 | — |
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter and Fiscal Year 2026. [Operator Instructions] I would now like to turn the call over to David Clair, Bio-Techne's Vice President, Investor Relations. Please go ahead. David Clair: Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal 2025 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K as well as the company's other SEC filings are available on the company's website within its Investor Relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to most comparable GAAP measures are available in the company's press release issued earlier this morning on the Investor Relations section of our Bio-Techne Corporation website at www.bio-techne.com. Separately, in the coming weeks, we will be participating in the Bank of America and Jefferies Healthcare Conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim. Kim Kelderman: Thank you, Dave, and good morning, everyone. Welcome to Bio-Techne's Third Quarter Earnings Call for Fiscal 2026. The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment. Our quarterly performance was supported by sustained strength from our large pharmaceutical customers and stable to improving trends in our U.S. academic end market. These positives were partially offset by continued softness in emerging biotech spending, resulting in a 2% organic revenue decline for the quarter. Importantly, we are seeing encouraging indicators that point to an ongoing improvement in the U.S. academia and an eventual recovery in emerging biotech, which positions us well for a stronger fiscal 2027. As discussed in our prior earnings call, order timing related to 2 cell therapy customers that received FDA Fast Track Designation along with the timing of a large OEM commercial supply order created a 400 basis point headwind in the quarter. Excluding these factors, underlying organic revenue growth was 2%. There were several notable highlights during our third quarter, including the following: our Spatial Biology portfolio delivered mid-teens growth and exited the …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Kim Kelderman | Chief Executive Officer, President & Director | USD 2,288,390 | Male | 1968 | Active |
James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | USD 1,667,089 | Male | 1971 | Active |
William A. Geist | President of Protein Sciences Segment | USD 1,339,266 | Male | 1969 | Active |
Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | USD 835,661 | Male | 1976 | Active |
Gerry Andros | Vice President of Sales and Marketing | — | Male | — | Active |
Luca Cicchetti | Managing Director | — | Male | — | Active |
Martin Wirtz | Senior Vice President of Strategy & Corporate Development | — | Male | — | Active |
Steve Crouse | President of Diagnostics & Spatial Biology Segment | — | Male | 1973 | Active |
Dylan Malayter | Senior Vice President of Reagent Solutions Division | — | Male | — | Active |
Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | — | Female | — | Active |
David Clair | Vice President of Investor Relations | — | Male | — | Active |
Bernie Andruss | Senior Vice President of Bio-Techne Diagnostics Division | — | — | — | Active |
Gary J. Latham | Vice President & Chief Technology Officer | — | — | — | Active |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
California State Teachers Retirement System lifted its position in Bio-Techne Corp (NASDAQ: TECH) by 24.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,164 shares of the biotechnology company's stock after purchasing an additional 35,772 shares during the quarter. California State
CMB.TECH FLEET UPDATE ANTWERP, Belgium, 3 August 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold one VLCC, generating a capital gain of approximately 74.4 million USD. Euronav CMB.TECH has sold the VLCC Donoussa (2016, 299,999 dwt).
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.
